NanoString Technologies
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 126m | 117m | 145m | 127m | 177m | 210m | 240m |
| % growth | 18 % | (7 %) | 24 % | (12 %) | 39 % | 19 % | 14 % |
| EBITDA | (80.8m) | (87.3m) | (108m) | (152m) | (81.5m) | (30.3m) | 5.3m |
| % EBITDA margin | (64 %) | (74 %) | (74 %) | (119 %) | (46 %) | (14 %) | 2 % |
| Profit | (40.7m) | (110m) | (115m) | (160m) | (152m) | (96.4m) | (77.2m) |
| % profit margin | (32 %) | (94 %) | (79 %) | (125 %) | (86 %) | (46 %) | (32 %) |
| EV / revenue | 7.6x | 23.1x | 12.6x | 3.4x | 0.9x | 1.1x | 1.0x |
| EV / EBITDA | -11.8x | -31.0x | -17.0x | -2.8x | -2.0x | -7.3x | 43.0x |
| R&D budget | 68.0m | 62.9m | 69.5m | 70.8m | - | - | - |
| R&D % of revenue | 54 % | 54 % | 48 % | 56 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
$3.8m | Series A | ||
$8.5m | Series B | ||
$30.0m | Series C | ||
| N/A | $15.0m | Late VC | |
| N/A | $2.5m | Debt | |
$20.0m | Series D | ||
$15.0m | Debt | ||
$15.3m | Series E | ||
N/A | Early VC | ||
$54.0m | IPO | ||
$45.0m | Post IPO Debt | ||
| N/A | $56.0m | Post IPO Equity | |
* | N/A | $40.0m | Post IPO Equity |
| N/A | $46.8m | Post IPO Equity | |
| N/A | $68.3m | Post IPO Equity | |
* | N/A | $175m | Post IPO Convertible |
* | N/A | $230m | Post IPO Equity |
* | N/A | N/A | Bankruptcy |
* | N/A | $12.5m | Post IPO Debt |
* | $393m Valuation: $393m | Acquisition | |
| Total Funding | $92.6m | ||
Related Content
Recent News about NanoString Technologies
EditNanoString Technologies, now a part of Bruker Corporation, is a biotechnology company that specializes in spatial biology and molecular profiling. The company operates in the life sciences sector, focusing on providing advanced tools and solutions for researchers and clinicians. NanoString's primary offerings include spatial transcriptomics and proteomics, which are techniques used to study the expression of genes and proteins within the context of tissue architecture. This allows for a deeper understanding of diseases, particularly cancer, by examining how cells interact within their native environments.
NanoString serves a diverse range of clients, including academic research institutions, pharmaceutical companies, and clinical laboratories. These clients use NanoString's technology for various applications such as drug development, biomarker discovery, and single-cell research. The company's products are designed to accelerate scientific discovery and improve the human condition by providing high-resolution insights into biological processes.
The market NanoString operates in is highly specialized and rapidly growing, driven by the increasing demand for precision medicine and advanced diagnostic tools. The company's business model is based on selling its proprietary instruments, consumables, and software solutions. Additionally, NanoString offers services such as data analysis and certified service provider programs, which generate recurring revenue streams.
NanoString makes money through the sale of its high-tech instruments like the GeoMx Digital Spatial Profiler and the nCounter Analysis System. It also earns revenue from consumables required for these instruments, such as assay kits and reagents. Furthermore, the company provides specialized data analysis services and maintains a global network of certified service providers, adding another layer of revenue.
In summary, NanoString Technologies is a key player in the spatial biology market, offering cutting-edge tools for gene and protein analysis. Its innovative solutions are essential for advancing research in oncology, drug development, and other life sciences fields.
Keywords: spatial biology, molecular profiling, gene expression, proteomics, cancer research, drug development, biomarker discovery, precision medicine, life sciences, biotechnology.